Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread widely, causing coronavirus disease 2019 (COVID-19) and significant mortality. However, data on viral loads and antibody kinetics in immunocompromised populations are lacking. We aimed to determine nasopharyngeal and plasma viral loads via RT-PCR and SARS-CoV-2 serology via ELISA and study their association with severe forms of COVID-19 and death in kidney transplant recipients. In this study we examined hospitalized kidney transplant recipients with non-severe (n = 21) and severe (n =19) COVID-19. SARS-CoV-2 nasopharyngeal and plasma viral load and serological response were evaluated based on outcomes and disease severity. Ten recipients (25%) displayed persistent viral shedding 30 days after symptom onset. The SARS-CoV-2 viral load of the upper respiratory tract was not associated with severe COVID-19, whereas the plasma viral load was associated with COVID-19 severity (p=0.0087) and mortality (p=0.024). All patients harbored antibodies the second week after symptom onset that persisted for two months. We conclude that plasma viral load is associated with COVID-19 morbidity and mortality, whereas nasopharyngeal viral load is not. SARS-CoV-2 shedding is prolonged in kidney transplant recipients and the humoral response to SARS-CoV-2 does not show significant impairment in this series of transplant recipients.
Competing Interest Statement
Dr. Caillard reports personal fees and non-financial support from Novartis, non-financial support from Sanofi, non-financial support from Astellas, outside the submitted work . All the others authors of this manuscript have no conflicts of interest to disclose.
Funding Statement
Acknowledgments/funding: this study was supported by the Strasbourg University Hospital (COVID-HUS study-HUS N 7760).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was reviewed and approved by the local Institutional Review Board (approval number: DC-2013-1990).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data supporting the findings of this study are available from the corresponding author upon reasonable request.
Abbreviations
- AUC
- area under curve
- BMI
- body mass index
- CNI
- calcineurin inhibitor
- COVID-19
- coronavirus disease-2019
- CRP
- C-reactive protein
- CT
- computed tomography
- D
- day after symptom onset
- ELISA
- enzyme-linked immunosorbent assay
- ICU
- intensive care unit
- Ig
- immunoglobulin
- IL
- interleukin
- KTR
- kidney transplant recipients
- MMF
- mycophenolate mofetil
- MPA
- mycophenolic acid
- mTOR
- mammalian target of rapamycin
- RdRp
- RNA-dependent RNA polymerase
- ROC
- receiver operating characteristic
- RT-PCR
- reverse transcription-polymerase chain reaction
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus-2
- S/CO
- absorbance values divided by the cutoff
- WHO
- World Health Organization
